Actively Recruiting
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
Led by Eli Lilly and Company · Updated on 2026-04-20
127
Participants Needed
14
Research Sites
149 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to generate evidence of the safety, tolerability, and pharmacokinetics/pharmacodynamics of IV LY4006896 compared with placebo in healthy participants and participants with Parkinson's disease.
CONDITIONS
Official Title
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Body mass index between 18 and 34 kg/m²
- For Japanese participants: participant and all biological parents and grandparents must be of Japanese descent and born in Japan
- Venous access suitable for IV blood sampling or drug administration
- For Part A (SAD) only: age 30 to 85 years and overtly healthy
- For Chinese participants in Part A: all four biological grandparents must be of Chinese descent and born in China
- For Part B (MAD) only: age 40 to 85 years
- For Part B only: diagnosed with Parkinson's disease per UK Brain Bank criteria
- For Part B only: if untreated, clinical status not expected to require treatment changes within 52 weeks
- For Part B only: if treated, stable dose of dopaminergic therapy for at least 90 days and not expected to change within 52 weeks
- For Part B only: Montreal Cognitive Assessment score of 24 or higher
You will not qualify if you...
- Significant neurological disease affecting the CNS other than Parkinson's disease in Part B
- Serious or unstable illnesses or conditions that could interfere with study or increase risk or limit life expectancy to less than 24 months
- Allergies to LY4006896, related compounds, transferrin receptor antibodies, or humanized monoclonal antibodies
- Severe multiple drug allergies or intolerance to topical corticosteroids
- History or presence of uncontrolled asthma, significant autoimmune disease, hereditary angioedema, or common variable immune deficiency
- Clinically significant anemia
- For Part A only: abnormal blood pressure or pulse rate or history of hypertension
- For Part B only: abnormal blood pressure or pulse rate or uncontrolled hypertension (systolic >150 mm Hg or diastolic >95 mm Hg)
- For Part B only: implanted deep brain stimulation or other neurostimulation devices
- For Part B only: receiving continuous infusion therapy with anti-parkinsonian medications such as subcutaneous foslevodopa-foscarbidopa or apomorphine or intestinal levodopa formulations
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 14 locations
1
Collaborative Neuroscience Network - CNS
Los Alamitos, California, United States, 90720
Actively Recruiting
2
Collaborative Neuroscience Network - CNS
Los Alamitos, California, United States, 90720
Actively Recruiting
3
K2 Medical Research, LLC
Maitland, Florida, United States, 32751
Completed
4
Aqualane Clinical Research
Naples, Florida, United States, 34105
Actively Recruiting
5
Charter Research
Orlando, Florida, United States, 32803
Actively Recruiting
6
Progressive Medical Research
Port Orange, Florida, United States, 32127
Actively Recruiting
7
K2 Medical Research, LLC
The Villages, Florida, United States, 32159
Actively Recruiting
8
Charter Research
The Villages, Florida, United States, 32162-2698
Actively Recruiting
9
QUEST Research Institute
Farmington Hills, Michigan, United States, 48334
Actively Recruiting
10
PPD Development, LP
Austin, Texas, United States, 78744
Actively Recruiting
11
Evergreen Health Research
Kirkland, Washington, United States, 98034
Not Yet Recruiting
12
Inland Northwest Research
Spokane, Washington, United States, 99202
Not Yet Recruiting
13
P-One Clinic
Hachiōji, Japan, 192-0071
Actively Recruiting
14
Oita University Hospital
Yufu, Japan, 879-5593
Actively Recruiting
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
P
Physicians interested in becoming principal investigators please contact
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here